FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Biologics

Petition Urges FDA to Overhaul Biosimilar Approval Rules

A biosimilars scholar files a citizen petition urging FDA to dramatically streamline and modernize its biosimilar approval requirements.

latest-news-card-1
Biologics

FDA OKs 1st Cellular Therapy for Severe Aplastic Anemia

FDA approves Gamida Cells Omisirge, the first cellular therapy authorized to treat patients with severe aplastic anemia.

latest-news-card-1
Human Drugs

FDA Delays Safety Review of Abortion Pill Mifepristone

FDA postpones a promised safety review of the abortion drug mifepristone and is now not likely to be released until after the 2026 midterm elections.

latest-news-card-1
Human Drugs

Praxis Epilepsy Drug Study Stopped for Positive Efficacy

Praxis Precision Medicines says its experimental epilepsy drug relutrigine produced positive results in a key study, prompting an independent committe...

latest-news-card-1
Human Drugs

FDA 483 Cites Apotex Over Sterility, Data Integrity Failures

FDA investigators issue a 24-page Form FDA-483 citing numerous manufacturing violations after a 12-day inspection in May of Apotexs sterile drug facil...

latest-news-card-1
Biologics

Panel Votes to End Newborn Hepatitis B Shot Recommendation

CDCs Advisory Committee on Immunization Practices votes to discontinue the longstanding policy that all newborns receive the Hepatitis B vaccine withi...

latest-news-card-1
Medical Devices

FDA Advisers Reject J&Js V-Wave Heart Shunt

An FDA advisory committee votes unanimously against recommending approval of Johnson & Johnsons V-Wave heart shunt for patients with advanced heart fa...

latest-news-card-1
Human Drugs

Device Compliance Official Flags Quality Gaps, Rising Enforcement

A senior CDRH compliance official warns industry that persistent shortcomings in complaint handling, corrective actions, and medical device reporting ...

latest-news-card-1
Human Drugs

Breyanzi OKd for Hard-to-Treat Marginal Zone Lymphoma

FDA approves Juno Therapeutics CAR-T therapy lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma.

latest-news-card-1
Human Drugs

Bayesian Statistical Analysis Demonstration Project

FDA solicits proposals for the CDER Center for Clinical Trial Innovation Bayesian Statistical Analysis demonstration project.